Startseite Kongressberichte 2021 63rd ASH Annual Meeting and Exposition In-Person/Virtual Cellular Therapies Expanding Targets and Cellular Sources for Immunotherapies

704. Cellular Immunotherapies: Expanding Targets and Cellular Sources for Immunotherapies

823
Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, Armin Ghobadi, Krish Patel, et al.

Please consult the abstract

 

824
A Comparison Study of Anti-CLL1 CART Cells Equipped with Different Co-Stimulatory Domains in the Treatment of Children with Refractory/Relapsed Acute Myeloid Leukemia

Kunlin PEI, Haoyu Xu, Peng-Fei Wang, et al.

Please consult the abstract

 

825
Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

David A. Sallman, Hany Elmariah, Kendra Sweet, et al.

Please consult the abstract

 

826
Novel CD19-Specific γ/δ TCR-T Cells in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Chenggong Li, Qi Chang, Jing Wang, et al.

Please consult the abstract

 

827
Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Sham Mailankody, Claudia Diamonte, Lisa Fitzgerald, et al.

Please consult the abstract

 

828
Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial)

Douglas E Gladstone, Christopher Howard, Mi-Ae Lyu, et al.

Please consult the abstract